AI Proteins, an innovative biotech firm focusing on developing a new class of therapeutic miniproteins through artificial intelligence, has announced the appointment of Dr. James Bowman, PhD, as its first Chief Technology Officer. In this new position, James will lead the growth of the company’s core technology platform, which combines machine learning, synthetic biology, robotics, and extensive data analysis to create groundbreaking protein therapeutics. Prior to this role, he served as AI Proteins’ Director of Protein Engineering, where he played a crucial role in establishing the framework that drives the company's discovery engine.

“Our vision is to bring miniprotein medicines to patients across many diseases. Accomplishing this requires industrializing the design-build-test process for drug discovery,” stated Dr. Chris Bahl, CEO of AI Proteins. “James has been pivotal in building our protein engineering approach, and his promotion to CTO underscores both his contributions and our commitment to advancing the technology at the heart of AI Proteins.”

Before joining AI Proteins as a founding member, James was a Postdoctoral Fellow at the Institute for Protein Innovation, Boston Children’s Hospital, and Harvard Medical School. There, he engineered innovative miniproteins for cancer therapeutics, leading to several patent applications and licenses.

""I'm incredibly excited to take on the role of CTO, and doubly thrilled to be leading our efforts to make our discovery engine even more amazing,"" remarked James Bowman. “We built a rapid, high-throughput approach for creating miniproteins with properties and functions that we pre-define and tailor to each project’s design goals. Miniproteins offer unique advantages over existing modalities, and our platform will allow this modality to reach its full potential in medicine.”

About AI Proteins

AI Proteins, based in Boston, is dedicated to transforming protein therapeutics through a novel method of designing entirely new proteins. Utilizing AI-driven design and a high-throughput drug discovery platform, the company develops de novo miniproteins optimized for various therapeutic uses. Collaborating with leading biopharmaceutical companies, AI Proteins actively seeks partnerships across diverse therapeutic areas while advancing its internal pipeline. The AI Proteins platform holds the potential to significantly speed up the development of lead therapeutic candidates ready for IND-enabling studies.

For more information, please visit aiproteins.com.

‍